浙江震元(000705) - 2024 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2024 was ¥892,781,471.42, a decrease of 11.13% compared to the same period last year[2]. - Net profit attributable to shareholders was ¥44,966.67, down 99.76% year-on-year[2]. - The net profit after deducting non-recurring gains and losses was -¥1,246,760.03, a decline of 107.54% compared to the previous year[2]. - The company experienced a 37.59% decline in operating profit, totaling ¥58,359,002.09, attributed to increased competition and adjustments in the pharmaceutical wholesale business[5]. - The total profit for the period was ¥62,094,740.29, down 33.49% year-on-year[5]. - The company reported a 38.26% decrease in net profit, amounting to ¥45,017,860.97, influenced by market competition and increased financial costs[5]. - The company's net profit attributable to minority shareholders decreased by 52.09% to ¥1,448,919.19 compared to ¥3,024,126.33 in the same period last year[6]. - Net profit for Q3 2024 was approximately RMB 17.08 million, a decline of 16.5% from RMB 20.46 million in the same period last year[13]. - Basic earnings per share for Q3 2024 were RMB 0.1304, down from RMB 0.2092 in the same period last year, reflecting a decrease of 37.5%[13]. Cash Flow and Investments - The net cash flow from operating activities was ¥20,844,197.73, a decrease of 29.54% year-on-year[2]. - The net cash flow from investing activities dropped by 421.14% to -¥206,815,940.69, primarily due to increased investments in subsidiaries[6]. - The net cash flow from financing activities increased by 372.76% to ¥139,998,625.49, mainly due to increased bank loans from subsidiaries[6]. - The net increase in cash and cash equivalents decreased by 35.45% to ¥90,754,851.44 compared to ¥140,605,844.58 in the previous period[6]. - Cash paid for the purchase of fixed assets and intangible assets in Q3 2024 was approximately ¥219.29 million, an increase of 69.2% compared to ¥129.70 million in the same period last year[14]. - The net cash received from the disposal of fixed assets was approximately ¥3.83 million, up from ¥0.92 million year-over-year[14]. Assets and Liabilities - Total assets at the end of the reporting period were ¥3,266,970,513.78, an increase of 11.16% from the end of the previous year[2]. - Total liabilities amounted to RMB 1,292,896,630.46, up from RMB 940,293,365.01, marking an increase of around 37.5%[12]. - The company's total equity decreased slightly to RMB 1,974,073,883.32 from RMB 1,998,785,851.36, a decline of about 1.2%[12]. - Long-term investments in equity reached RMB 154,359,444.00, down from RMB 175,663,544.03, indicating a decrease of approximately 12.1%[12]. - The total non-current assets increased to RMB 1,239,010,507.54 from RMB 1,067,659,591.87, reflecting a growth of approximately 16.0%[12]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 40,720, with the largest shareholder holding 24.93% of the shares[7]. - The company has not disclosed any related party relationships among its major shareholders[8]. Research and Development - The company increased its R&D expenses due to ongoing investments in the industrial sector, impacting overall profitability[6]. - Research and development expenses for Q3 2024 were approximately RMB 38.37 million, an increase of 19.2% compared to RMB 32.24 million in the same period last year[13]. Market Challenges - The company is facing challenges from consumer downgrade, intensified competition, and medical insurance cost control, leading to a decline in high-margin product sales[6]. Audit Status - The third-quarter report was not audited, indicating that the financial figures are preliminary[11].